TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11128679

Group type: EXPERIMENTAL
Intervention: Probenecid and aspirin 325 mg taken concomitantly
Number of subjects: 11

Group type: COMPARATOR
Intervention: Probenecid alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Probenecid followed by aspirin 325 mg at 6 hours
Number of subjects: 11
Study: 8981334

Group type: EXPERIMENTAL
Intervention: Oesclim 50
Number of subjects: 283

Group type: COMPARATOR
Intervention: Estraderm TTS 50
Number of subjects: 283
Study: 1478369

Group type: EXPERIMENTAL
Intervention: Intensive treatment (continuous subcutaneous insulin infusion)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 27
Study: 6487749

Group type: EXPERIMENTAL
Intervention: Ketoprofen capsules (200 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sustained-release pellets (200 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sustained-release pellets (200 mg) once every 24 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ketoprofen capsules (50 mg) every 6 h
Number of subjects: 9
Study: 30323322

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (5-day course)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 28738672

Group type: EXPERIMENTAL
Intervention: Compression stockings group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Full‐leg compression group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Shorts group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Full‐leg compression garments
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no compression garments)
Number of subjects: 18
Study: 26792812

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice daily
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 24593917

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (annual treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Annual treatment with oral azithromycin
Number of subjects: 32
Study: 22822195

Group type: EXPERIMENTAL
Intervention: Lumbar plexus block (LPB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no LPB)
Number of subjects: 42
Study: 20699411

Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 mg [(14)C]INCB018424
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily oral doses of unlabeled INCB018424
Number of subjects: 0
Study: 16988883

Group type: EXPERIMENTAL
Intervention: Education videotape
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Contact videotape
Number of subjects: 244
Study: 15773875

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulphate (40 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12114361

Group type: EXPERIMENTAL
Intervention: Clarithromycin (400 mg/d for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin (1,500 mg/d for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor (750 mg/d for 7 days)
Number of subjects: 0
Study: 11149429

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (2 microg/kg)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 265
Study: 8795409

Group type: EXPERIMENTAL
Intervention: Isothermic irrigation fluid (Group 1)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Room temperature irrigation fluid (Group 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 1459356

Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (1 pmol/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] (0.3 pmol/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of GIP and GLP-1 [7-36 amide]
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl with 1% albumin)
Number of subjects: 9
Study: 4067972

Group type: EXPERIMENTAL
Intervention: Ingestion of a large meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Repeating the experiment without food or with salt content only
Number of subjects: 8
Study: 31024969

Group type: EXPERIMENTAL
Intervention: Danirixin (DNX)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Danirixin + Oseltamivir (DNX+OSV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oseltamivir (OSV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29656838

Group type: EXPERIMENTAL
Intervention: PARO intervention (robotic seal)
Number of subjects: 138
Study: 27998876

Group type: EXPERIMENTAL
Intervention: iPST
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Project: EVO
Number of subjects: 626

Group type: COMPARATOR
Intervention: Health Tips
Number of subjects: 626
Study: 23860287

Group type: EXPERIMENTAL
Intervention: Mixed maximal and explosive strength training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Circuit training with body weight (Control)
Number of subjects: 34

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Men (experimental)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Women (experimental)
Number of subjects: 34
Study: 22500712

Group type: EXPERIMENTAL
Intervention: Chinese medicine (1 bag/dose, two doses per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil (5mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study: 20801256

Group type: EXPERIMENTAL
Intervention: Lateral subtalar sling taping
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fibular repositioning taping
Number of subjects: 16

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 16
Study: 18981842

Group type: EXPERIMENTAL
Intervention: Watertight dural closure (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Secondary watertight dural closure (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Adaptive dural closure (Group C)
Number of subjects: 150
Study: 15911537

Group type: EXPERIMENTAL
Intervention: Lumbar spine fusion
Number of subjects: 349

Group type: COMPARATOR
Intervention: Intensive rehabilitation programme
Number of subjects: 349
Study: 12885685

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) with Primary Care Management (PCM)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) with Cognitive Behavior Therapy (CBT)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Naltrexone with PCM
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Naltrexone with CBT
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo with PCM
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo with CBT
Number of subjects: 197
Study: 10369493

Group type: EXPERIMENTAL
Intervention: Chitosan (four capsules twice daily for 28 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (indistinguishable capsules, four capsules twice daily for 28 days)
Number of subjects: 34
Study: 7585493

Group type: EXPERIMENTAL
Intervention: Fatalism
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: FOBT participation
Number of subjects: 192
Study: 2373656

Group type: EXPERIMENTAL
Intervention: Prompted group (16 parents)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (16 parents)
Number of subjects: 32
Study: 6156364

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 31432556

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 30207136

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg, followed by an infusion of 0.4 μg/kg/h
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 68
Study: 27977825

Group type: EXPERIMENTAL
Intervention: LMCAF-M (laterally moved coronally advanced flap with microsurgical instruments)
Number of subjects: 50

Group type: COMPARATOR
Intervention: LMCAF-C (conventional laterally moved coronally advanced flap)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LMCAF-M
Number of subjects: 50

Group type: COMPARATOR
Intervention: LMCAF-C
Number of subjects: 50
Study: 24092869

Group type: EXPERIMENTAL
Intervention: Water method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Alcohol method
Number of subjects: 72
Study: 23502220

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 43
Study: 21849374

Group type: EXPERIMENTAL
Intervention: Combined exercise training (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Endurance training (n=15)
Number of subjects: 45
Study: 19650754

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 17452069

Group type: EXPERIMENTAL
Intervention: Shock group (converted to ventricular fibrillation and were shocked)
Number of subjects: 738
Study: 15690976

Group type: EXPERIMENTAL
Intervention: Human neuronal cells (hNT cells; LBS neurons) delivered in doses of 2 or 6 million cells in three or nine implants, or 5 or 10 million cells in 25 implants
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Stereotactic surgical technique for cell delivery
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cell delivery cannula
Number of subjects: 26
Study: 11198904

Group type: EXPERIMENTAL
Intervention: Providing feedback about prior performance and confidence on specific test questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 9453272

Group type: EXPERIMENTAL
Intervention: Patients with chronic tension-type headache
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 8091321

Group type: EXPERIMENTAL
Intervention: Salmeterol 25, 50, 100, and 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol 100, 500, 1000, and 1000 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2663742

Group type: EXPERIMENTAL
Intervention: Maltodextrin-based beverage (Mf) (20% w/v, 85% maltodextrin, 15% fructose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fructose-maltodextrin beverage (FM) (50/50%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal CHO-rich diet (N) (60 En%)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Maltodextrin-based beverage (Mf)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal CHO-rich diet (N)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fructose-maltodextrin beverage (FM)
Number of subjects: 13
Study: 787957

Group type: EXPERIMENTAL
Intervention: Propranolol (80-320 mg daily, with increments up to 1200 mg as needed)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Tranquilizers (control group)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo (single-blind trials)
Number of subjects: 725
Study: 31931026

Group type: EXPERIMENTAL
Intervention: Resin infiltration (Icon, pre-product; DMG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mock treatment (control)
Number of subjects: 22
Study: 28430638

Group type: EXPERIMENTAL
Intervention: TACE+C+L
Number of subjects: 71

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 71
Study: 26293519

Group type: EXPERIMENTAL
Intervention: Piperaquine-dihydroartemisinin administered after a high-fat, high-calorie meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperaquine-dihydroartemisinin administered after fasting
Number of subjects: 0
Study: 23526799

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nembutal
Number of subjects: 2
Study: 21651652

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 42
Study: 19793357

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 2366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: All alogliptin groups
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 2366
Study: 17151088

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiepileptic drugs
Number of subjects: 0
Study: 15128167

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) signal indices at T1-weighted images (T1WI)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: MRI signal indices at S1 of T1WI
Number of subjects: 138

Group type: COMPARATOR
Intervention: MRI signal indices
Number of subjects: 138
Study: 11501891

Group type: EXPERIMENTAL
Intervention: Postfitting electroacoustic adjustments based on participant complaints/observations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no adjustments made)
Number of subjects: 0
Study: 9525716

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with CCNU, vincristine, and prednisone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with eight-drugs-in-1-day regimen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation with a local boost to the primary tumor
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Extent of resection (total vs less than total)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Residual tumor size (< or = 1.5 cm2 vs > 1.5 cm2)
Number of subjects: 32
Study: 8071052

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 173

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 173

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 173
Study: 2568086

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg h.s.
Number of subjects: 375

Group type: COMPARATOR
Intervention: Cimetidine 800 mg h.s.
Number of subjects: 375
Study: 30453981

Group type: EXPERIMENTAL
Intervention: Deferasirox film-coated tablet (FCT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Deferasirox dispersible tablets (DT)
Number of subjects: 173
Study: 28669049

Group type: EXPERIMENTAL
Intervention: Endoscopic tympanoplasty
Number of subjects: 13

Group type: COMPARATOR
Intervention: Microscopic tympanoplasty
Number of subjects: 13
Study: 26092557

Group type: EXPERIMENTAL
Intervention: Docetaxel chemotherapy plus androgen deprivation therapy (ADT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 30
Study: 24281776

Group type: EXPERIMENTAL
Intervention: Polyurethane film dressing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 38
Study: 21933436

Group type: EXPERIMENTAL
Intervention: In-home multicomponent cognitive behavioural programme (7 sessions: 3 home visits and 4 telephone contacts)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: In-home multicomponent cognitive behavioural programme
Number of subjects: 389
Study: 18972062

Group type: EXPERIMENTAL
Intervention: Cu-(II)-orotate-dihydrate (8 mg Cu daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16550600

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 100 mg/m2 day 1 and etoposide 120 mg/m2 days 1-3 for 6 cycles)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin and etoposide)
Number of subjects: 140
Study: 12963761

Group type: EXPERIMENTAL
Intervention: 1000 mg of acetaminophen, given six times daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 10693916

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 30
Study: 9282151

Group type: EXPERIMENTAL
Intervention: Standardized Patients (SPs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Role Playing
Number of subjects: 120
Study: 7917773

Group type: EXPERIMENTAL
Intervention: lazabemide (100-300 mg single dose and 100-350 mg twice daily for 7 days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: lazabemide
Number of subjects: 75
Study: 2844876

Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (LTE4) (6.1 nmol, geometric mean)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (lower dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (higher dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leukotriene E4
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (in normal subjects)
Number of subjects: 8
Study: 29672869

Group type: EXPERIMENTAL
Intervention: Fresh blood stored not more than 7 days
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard-issue blood
Number of subjects: 372
Study: 28370172

Group type: EXPERIMENTAL
Intervention: Nurse-led care programme (part of a randomized controlled trial)
Number of subjects: 10
Study: 26130002

Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training (VR‐JIT)
Number of subjects: 39
Study: 24307896

Group type: EXPERIMENTAL
Intervention: TOMUS (retropubic midurethral sling)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: SISTEr (fascial sling)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1252
Study: 21214415

Group type: EXPERIMENTAL
Intervention: Manual acupuncture at bilateral acupoints LI‐4 and ST‐44
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham procedure with needle inserted bilaterally 1‐1.5 cm outside each acupoint
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control procedure with quiet rest for 20 minutes
Number of subjects: 12
Study: 18492534

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy (20 to 40 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 16567913

Group type: EXPERIMENTAL
Intervention: Intravenous injection of magnesium sulphate 250 mg/kg within half an hour of birth and subsequently 125 mg/kg at 24 and 48 hours of life
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no magnesium treatment)
Number of subjects: 40
Study: 14563897

Group type: EXPERIMENTAL
Intervention: Recombinant phenotype (r-PHT) interpretation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Virtual phenotype (v-PHT) interpretation
Number of subjects: 180

Group type: COMPARATOR
Intervention: VGI interpretation
Number of subjects: 180
Study: 10625787

Group type: EXPERIMENTAL
Intervention: Hydromer‐coated polyurethane stents (HCPS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard polyethylene stents
Number of subjects: 83
Study: 9184975

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients infected by Pseudomonas aeruginosa
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciliary ultrastructure in cystic fibrosis patients
Number of subjects: 12
Study: 1286497

Group type: EXPERIMENTAL
Intervention: Flumazenil (mean dose: 0.73 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo (mean dose: 8.9 ml)
Number of subjects: 154
Study: 3521855

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acetaminophen with codeine
Number of subjects: 50
Study: 31837382

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine
Number of subjects: 41
Study: 29493118

Group type: EXPERIMENTAL
Intervention: fast-acting insulin aspart (faster aspart)
Number of subjects: 41
Study: 26962719

Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum dose 1200 mg three times a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24746549

Group type: EXPERIMENTAL
Intervention: Low-intensity dietary intervention delivered via telephone and mail, including low‐literacy self‐help booklets and personalized dietary feedback
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (general population)
Number of subjects: 183
Study: 23442389

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 0
Study: 20841998

Group type: EXPERIMENTAL
Intervention: Suprathel
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Biatain‐Ibu
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mepitel
Number of subjects: 77
Study: 18165398

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 652

Group type: COMPARATOR
Intervention: D&C
Number of subjects: 652
Study: 15937595

Group type: EXPERIMENTAL
Intervention: Planned Caesarean
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 1159
Study: 12502656

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10593710

Group type: EXPERIMENTAL
Intervention: Various fixed-dose combination (FDC) formulations of rifampicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference administered as loose (separate) formulations
Number of subjects: 0